[目的]探讨18F-FDG PET/CT显像在血清肿瘤标志物CA199水平升高诊断中的应用价值.[方法]15例血CA199水平升高者行18F-FDG PET/CT显像,并对结果进行分析.[结果]15例血CA199升高者18F-FDG PET/CT显像发现恶性病变仅1例,余皆为良性病变,14例良性病变包括胆结石3例、胆囊炎2例、慢性胰腺炎1例、肝硬化2例、卵巢畸胎瘤2例和糖尿病4例.18F-FDG PET/CT显像对恶性肿瘤的检出率为6.7％.[结论]当患者血CA199水平升高时,应行常规影像学检查和血糖检测,排除良性病变,必要时行18F-FDG PET/CT显像.

Objective: To compare the18F-FDG cell binding in the drug-resistan breast cancer cell Bcap37/MDR1 and breast cancer cell Bcap37,to lay the foundation for a further study of the inhibitory effect of chemotherapy in breast cancer cell Bcap37/MDR1 and breast cancer cell Bcap37.Methods: Several different binding conditions were tested.① The cell number was 1.25×105~1×107/bottle.②The reaction time was 20~120 min.③The radioactivity of18F-FDG was 1.85~29.6 KBq.④The glucose concentration was 0~5.5 mmol/L.The count of CPM(B) in cells and CPM(F) in supernatant were measured by the γ equipment.The binding efficiency of Bcap37 and Bcap37/MDR1 cell with18F-FDG were calculated and compared.Result: When other conditions were invariable,and separately changed cell number,the reaction time and the18F-FDG radioactivity,the binding efficiency of Bcap37 was higher than the Bcap37/MDR1.The difference was significant(P<0.05).The difference of binding efficiency between Bcap37 and Bcap37/MDR1 cell at the 0 and 1.39 mmol/L groups was significant(P< 0.05);The difference of binding efficiency between Bcap37 and Bcap37/MDR1 cell at 2.78 mmol/L and 5.5 mmol/L groups was not statistically significant(P>0.05).Conclusions: The18F-FDG cell binding of breast cancer Bcap37/MDR1 was lower than the Bcap37.It showed that the proliferation and metabolism of drug resistance of tumor cells were lower than the parental tumor cells.